Cardiovascular-kidney-metabolic (CKM) syndrome involves the complex interaction of cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide are important therapeutic options for this syndrome. Evidence regarding the strength and maturity of this evidence varies across individual agents and outcomes. Current evidence indicates that large randomized controlled trials have demonstrated reductions in major adverse cardiovascular events with several GLP-1 receptor agonists. Additionally, dedicated evidence for clinically meaningful chronic kidney disease progression is strongest for semaglutide. Cardiovascular benefits of semaglutide have been demonstrated in individuals with overweight or obesity without type 2 diabetes, suggesting effects beyond glucose lowering. Tirzepatide shows substantial improvements in glycemic control and body weight, alongside expanding evidence for cardiovascular benefit, particularly in obesity-related heart failure with preserved ejection fraction. The evidence regarding tirzepatide’s impact on kidney function is less mature, primarily based on secondary and post-hoc analyses rather than a dedicated kidney outcome trial.